Key points from article :
Experimental drug targets gum disease bacteria to treat Alzheimer's.
Hypothesized that Porphyromonas gingivalis get into brain and cause inflammation.
High levels of this bacteria and its toxins were found in the brains of patients with Alzheimer's.
Oral drug COR388 can block the activity of toxins released by the bacteria.
Larger trials are needed to understand the consequences of having this bacteria in the brain.
Started a trial with 570 people having Alzheimer’s disease, which is due to give results in two years.
Research and development by Cortexyme, a US based clinical stage biopharmaceutical company.
